Public Health and Research News

ALEXANDRIA, VA–(Marketwire – August 26, 2010) –  This year, thousands of people in communities across the country will join the movement to Stop Diabetes® by participating in the American Diabetes Association’s Step Out: Walk to Fight Diabetes event. Step Out is a fundraising walk that takes place in more than 140 cities to raise awareness about diabetes and to raise much needed funds to help change the future of this growing epidemic that is taking a physical, emotional and financial toll on our country.

Step Out: Walk to Fight Diabetes is a family event for those who want to become involved in the community and help change the future of diabetes. Participants can walk as an individual or create a team and walk with friends, family, and co-workers.

Do you want to show what it is like to live with diabetes? The American Diabetes Association is also looking for Red Striders. A Red Strider is a person with diabetes who has a passion to stop diabetes and is willing to put a face on this disease by helping others understand what it takes to live with — and fight — this serious disease.

“On the day of Step Out, it is very important to recognize all of the people with diabetes,” said Christine Schaeberle, founder of one of the first Red Strider programs in Colorado. “By wearing red hats that signify that we are living with diabetes, we are able to recognize people with diabetes who are taking steps to stop diabetes.”

Join Christine and other Red Striders in the movement to Stop Diabetes as they ‘Step Out’ this year wearing their Red Strider red hats.

“The Red Strider program really opened my eyes to the fact that I am not alone and I am joined by so many other people who are living with diabetes. For people who participate in Step Out and don’t have diabetes themselves, this is a way for them to see the many faces of diabetes and reinforce the fact that diabetes affects people of all ages and ethnicities. These are the faces that encourage me to walk, and I am inspired to do all that I can do to fight this disease each and every day. I am encouraged to share my story with the hope that other people will join me in raising money to stop diabetes,” added Schaeberle.

Today, there are nearly 24 million children and adults in the United States who have diabetes. While nearly 18 million people have been diagnosed, there are 5.7 million people who don’t even know that they have the disease. If present trends continue, 1 in 3 Americans, and 1 in 2 minorities, will face a future with diabetes. To date, the American Diabetes Association has raised and donated more than $450 million for diabetes research.

National sponsors of Step Out: Walk to Fight Diabetes include Equal® Sweetener, Pure Via™ All Natural Zero Calorie Sweetener, Cary’s® Sugar Free Syrup and Walmart. Be a part of the cure and start raising money today. To register, volunteer or find out more information, please visit diabetes.org/stepout or call 1-888-DIABETES. Together we can stop diabetes. One step at a time.

About the American Diabetes Association
The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure, and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

ROSWELL, GA–(Marketwire – August 26, 2010) –  Economic globalization brings increased international business travel, and as a result, greater exposure to communicable illnesses.

The H1N1 pandemic that began last year in Mexico forced many companies to face this reality, and new threats are emerging continuously, with illnesses such as Yellow Fever, Hepatitis A & B, Malaria and Japanese Encephalitis confronting today’s business travelers.

The key to mitigating these threats is Passport Health (www.passporthealthusa.com), a leading provider of travel health information and immunizations for international travelers, major corporations, universities and other international organizations, and a Charter Sponsor of the recently launched PREACTION EMERGENCY RESPONSE ALLIANCE™.

The PREACTION ALLIANCE™ (www.preaction.com) is a first-of-its-type private network offering business continuity and disaster-response capabilities through a low monthly-fee, membership-based organization. By becoming a Charter Sponsor, Passport Health has provided its network of franchisees — which comprise more than 170 locations nationwide — access to a free annual membership in the PREACTION ALLIANCE. Thereafter, Member benefits can be retained for less than $1 a day.

“Passport Health is committed to the health and well-being of all employees and our Vaccine Specialists are mission-ready to respond quickly to PREACTION ALLIANCE Members’ needs, including disaster relief and emergency preparedness,” said Fran Lessans, Passport Health CEO.

“The question about pandemics is not if, but when they will happen. We just saw the impact that the H1N1 pandemic had on corporate productivity,” Lessans added. “All businesses should have a pandemic plan in place and have a plan to deliver antivirals to employees if necessary. Passport Health’s presence in the PREACTION ALLIANCE assures that vaccines are available to Members and that they can be administered in short notice.”

The PREACTION ALLIANCE was developed by Firestorm® (www.firestorm.com), a national leader in crisis management, threat assessment/risk analysis, and business continuity. Other Charter Sponsors include W.W. Grainger Inc., the leading supplier of maintenance, repair and operations products.

“The ability to travel the world is one of the great aspects of modern society. Unfortunately, introduction to unusual places, people, and cuisine is often accompanied by exposure to disease threats for which your body is ill-prepared,” said Dr. Don Donahue, Firestorm’s Director of Healthcare Response. “Overseas trips — for business or pleasure — should be preceded by a travel medicine consultation. Vaccination and prophylaxis are critical requirements in many corners of the globe.”

ALEXANDRIA, VA–(Marketwire – August 24, 2010) –  The American Diabetes Association is extremely disappointed by the federal district court decision yesterday blocking the federal government from funding research involving embryonic stem cells. 

President Obama’s Executive Order in March of 2009 assisted advancement of stem cell research by lifting existing restrictions on the use of embryonic stem cells, while maintaining strict ethical guidelines. Even prior to that Order, federal funding of stem cell research was permitted on a limited number of previously-existing stem cell lines.

“This is a major setback for medical research, in particular, research towards a cure for diabetes,” said Richard Bergenstal, MD, President, Medicine & Science, American Diabetes Association. “This decision stands as a roadblock to research that has shown great promise in finding a cure for diabetes and treating its complications.”

Stem cell research has the potential to save and significantly improve the lives of the nearly 24 million Americans with diabetes who face its many complications including heart disease, amputation and blindness. The American Diabetes Association has extensively advocated for stem cell research, which holds the promise of accelerating medical advancements in many fields. “We will work with other concerned organizations to find a way to remove this barrier to scientific progress,” said Bergenstal.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

MUNDELEIN, IL–(Marketwire – August 20, 2010) –  Medline Industries, Inc., the company that produced the original Pink Glove Dance, is looking for breast cancer survivors in the New York City and surrounding areas who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating more than 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves. Medline, based in Mundelein, Ill., is the largest privately held manufacturer and distributor of healthcare supplies in the country.

When and where will it be?
Filming will take place Saturday, August 28 at 10:00 a.m. at The Broadway Plaza in Times Square between 42nd and 43rd streets.

What are the qualifications to participate?
Participants need to be breast cancer survivors and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country inquired about participating in the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

MUNDELEIN, IL–(Marketwire – August 20, 2010) –  Medline Industries, Inc., the company that produced the original Pink Glove Dance, is looking for breast cancer survivors in the New York City and surrounding areas who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating more than 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves. Medline, based in Mundelein, Ill., is the largest privately held manufacturer and distributor of healthcare supplies in the country.

When and where will it be?
Filming will take place Saturday, August 28 at 10:00 a.m. at The Broadway Plaza in Times Square between 42nd and 43rd streets.

What are the qualifications to participate?
Participants need to be breast cancer survivors and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country inquired about participating in the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

MUNDELEIN, IL–(Marketwire – August 20, 2010) –  Medline Industries, Inc., the company that produced the original Pink Glove Dance, is looking for breast cancer survivors in the New York City and surrounding areas who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating more than 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves. Medline, based in Mundelein, Ill., is the largest privately held manufacturer and distributor of healthcare supplies in the country.

When and where will it be?
Filming will take place Saturday, August 28 at 10:00 a.m. at The Broadway Plaza in Times Square between 42nd and 43rd streets.

What are the qualifications to participate?
Participants need to be breast cancer survivors and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country inquired about participating in the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

GOLDEN VALLEY, MN–(Marketwire – August 19, 2010) –  Health Fair 11 at the Fair celebrates its tenth year of providing free or low-cost health screenings to people attending the Minnesota State Fair. 

During the past decade, fairgoers have flocked to the Health Fair 11 building to take advantage of great health-related offerings for people of all ages. Since 2001, 370,000 health screenings have been documented at Health Fair 11 at the Fair.

This year, Health Fair 11 building visitors will find blood pressure checks, diabetes screenings, bone density and body mass measurements, hearing and vision assessments, blood typing, balance evaluations, and free tote bags in which to carry health and wellness information materials they obtain from exhibitors. Fairgoers can step on the official weight scale, pick up information on food allergies and celiac disease, and have their children tested for lead exposure. 

New this year: Germ City and Great Hang Up
How clean are your hands? Does your child do a good job of washing his or her hands? Families can learn if they have good hand washing skills by taking a trip through the Minnesota Department of Health’s Germ City. The exhibit includes “glitterbug goo,” black light booths, and hand washing sinks.

Fairgoers will also have the opportunity to take KARE 11’s Great Hang Up pledge. The pledge is a public health campaign to convince people to not talk or text on a cell phone or other mobile device while driving. Health Fair 11 has created special “DRIVE NOW-Talk/TXT L8R” window clings to encourage people to take the pledge and then share the message. Clings will be available daily from 6 – 9 p.m.

Get a flu shot before school starts
Flu shots will be available daily from 9 a.m. to 6 p.m. Nurses with the nonprofit Minnesota Visiting Nurse Agency (MVNA) will vaccinate people ages three and older. Minors must be accompanied by a parent or guardian. Both the injectable vaccine and nasal spray vaccine will be available. The MVNA encourages people to bring proof-of-insurance cards. Parents: this is a perfect time to have your children vaccinated before they get exposed to the flu virus at school.

Location, location, location
Health Fair 11 at the Fair is located on the southwest corner of Dan Patch Ave. and Cooper St. The building is open daily from 9 a.m. to 9 p.m. The exhibit is made possible by Health Fair 11, a partnership of KARE TV, UCare, and North Memorial Medical Center. 

ALEXANDRIA, VA–(Marketwire – August 18, 2010) –  Alpha Kappa Alpha Sorority (AKA) is joining forces with the American Diabetes Association‘s African American Initiatives — known as Live EMPOWERED — to stop diabetes in the African American Community. The collaboration is driven by the reality that African Americans are greatly affected by diabetes; they are 1.8 times more likely to have type 2 diabetes than non-Latino whites. 

To combat this epidemic, beginning in the spring of 2011, the AKAs will designate 10 undergraduate chapters at Historically Black Colleges and Universities to lead diabetes workshops and activities. Through this initiative, the Sorority hopes to spread the message about how to prevent diabetes and provide tools to assist those with diabetes to live a productive life with this disease. In announcing the partnership, AKA’s newly installed international president Attorney Carolyn House Stewart stated, “Alpha Kappa Alpha Sorority’s goal is to help our community recognize the risks of this disease, its many complications and treatment options. We will host forums that will heighten awareness and offer prevention strategies to help eliminate this deadly disease that shortens lives and impacts the quality of life of many African Americans of all ages.” 

AKA and the American Diabetes Association share common priorities and interests in reaching African Americans, students and other key constituents with important awareness messaging relating to diabetes, including risk factors, prevention strategies, warning signs, and management of the disease.

Both organizations have unique competencies to address these issues and believe that there will be a greater opportunity to promote mutual goals through multiple communications channels. This collaboration is especially significant, because African-American women are at a greater risk for the number one complication of diabetes: heart disease.

“By getting this powerful group of women to join us in our movement to Stop Diabetes, we have the potential to change many lives and communities,” said Earnestine Walker, Director of Community Outreach at the American Diabetes Association.

About Alpha Kappa Alpha Sorority:
Founded in 1908, on the campus of Howard University in Washington, DC, Alpha Kappa Alpha (AKA) is the oldest Greek-lettered organization established by African-American college-educated women. AKA’s membership is comprised of 260,000 distinguished women in graduate and undergraduate chapters in the United States and abroad who boast excellent academic records, proven leadership skills, and who are involved in the global community through advocacy and service. Attorney Carolyn House Stewart is the 28th International President and will serve from 2010 – 2014. Her administration’s theme is “Global Leadership Through Timeless Service.”

About the American Diabetes Association:
The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

Click here to see all recent news from this company

CENTERVILLE, MA–(Marketwire – August 18, 2010) –  UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) is pleased to announce that it has signed an agreement with Trade Network, Inc., dba Creative Media and Buying Services, to produce a series of television advertisements in order to publicize a national awareness campaign featuring the ViraTech UV-400 product line, and its proven health benefits in relationship to the ongoing and growing dangers presented by poor indoor air quality in homes, and workplaces across the nation.

The commercials are slated to air beginning in October, just prior to the onset of the traditional flu season, and will be broadcast on a variety of national television networks at various airtimes. They will be broadcast throughout this heightened period of awareness and, as such, are designed to offer an informative and educational outlook demonstrating the design and proven effectiveness of the UV-400 bacteria killing air purifier in action.

The indoor air quality (“IAQ”) sector is a vast market that grows in significance every time an airborne illness penetrates public mainstream awareness. This generally occurs in the fall and spring seasons and is usually in the forefront of public awareness during the fall season when the Company’s advertisements are scheduled for broadcast.

“This campaign is expected to not only to raise national awareness of the ViraTech UV-400 and its ability to kill bacteria and other contaminants, but to also spotlight the epidemic increase in respiratory problems due to poor indoor air quality generally,” stated Jack Lennon, President of UV Flu Technologies. “These television spots are an integral part of our overall marketing plan intended to capture a significant percentage of the worldwide multibillion dollar air-purification and filtration product marketplace, by demonstrating a product that actually works, and which has been cleared by the FDA as a medical device specifically for killing bacteria. The UV-400 product, along with several other products currently under development is directly aimed at reducing the extraordinary number of deaths attributed to poor indoor air quality that occur around the world every year.”

The UV-400 is uniquely positioned to attract serious attention by consumers due to its listing as a Medical Device with the FDA which resulted after a battery of rigorous laboratory tests proved the UV-400 kills 99% of airborne bacteria in its patented UV chamber. The device is designed to easily circulate the air within the average home or work environment multiple times per hour, and will be demonstrated within a number of real life situations and applications throughout the television presentations.

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO

Click here to see all recent news from this company

LOUISVILLE, KY–(Marketwire – August 12, 2010) –  Bringing home the gold is always an incredible accomplishment. This year the University of Louisville along with its architectural team of SmithGroup and Arrasmith, Judd, Rapp, Chovan Inc. are basking in the glory of gold for the design and construction of the new Clinical and Translational Research Building.

In the quest to continue to excel in the biomedical sciences nationwide, the University’s Health Sciences Center (HSC) embarked on the design of the Clinical and Translational Research building (CTR) in 2004. The facility was to be a continuation of the goals of creating state-of-the-art research facilities in order to attract and retain the best researchers from among the nation, consolidate existing programs, and provide for the opportunity to augment on the success of programs already established within the HSC.

Completed in August 2009, the $109-million, 288,000 gsf facility consists of a combination of wet laboratories, laboratory support spaces, shared equipment/support areas, auditorium, and research faculty offices. The building’s bright, colorful and vibrant interior lab and office environments were designed to facilitate discovery and groundbreaking research. Of primary importance is the open laboratory concept utilized in the facility, which allowed lab planning experts to design laboratories as larger spaces housing various investigators rather than dedicated smaller modules assigned to a single investigator, thus increasing collaboration.

Achieving LEED Gold Certification was clearly one of the greatest accomplishments in this particular project. These days it is more common for buildings to pursue certification, but it is extremely rare that certification isn’t actually pursued until the project is well into construction. The design team, contractor and owner met to discuss the possibility of pursuing LEED late in the game and determined that certification would be achievable since the team incorporated various sustainable design measures from the beginning. These measures included providing daylighting to 75% of occupied spaces, selecting eco-friendly and recyclable materials, and commissioning all equipment including fumehoods.

The Clinical and Translational Research Building project is the fourth in a series of research buildings SmithGroup has designed with partner AJRC. SmithGroup and AJRC have a long history on the University of Louisville campus. Their partnership dates back over 30 years and includes research buildings, classrooms and clinical expansion at the University of Louisville campus. In addition, the team designed the university’s research tower, library center, dental school, clinical core hospital building, an ambulatory care building, and the Donald Baxter and Delia Baxter Research Buildings.

SmithGroup ranks as the 7^th largest architecture and engineering firm in the U.S. (Building Design & Construction “Giants” survey, July 2009) and employs 800. The firm is composed of client industry-focused practices serving the higher education, healthcare, workplace and science & technology markets.

With 346 LEED accredited professionals and 45 LEED certified projects, SmithGroup is a national leader in sustainable, environmentally intelligent design. Among its most noteworthy, recently completed projects are the dual LEED Platinum Christman Building, a corporate headquarters in Lansing, Mich.; the LEED Platinum Smart Home at Duke University, Durham, North Carolina; and the National Renewable Energy Lab’s Science & Technology Facility, Golden, Colo., the first LEED Platinum federal project.

Established in 1853, SmithGroup is the longest continually operating architecture and engineering firm in the U.S. 

TORONTO, ONTARIO–(Marketwire – Aug. 5, 2010) – The John Howard Society of Toronto will be releasing ‘Homeless and Jailed: Jailed and Homeless;’ a report on the increasing number of homeless individuals in Toronto area jails who are being released to areas that are unable to provide sufficient resources to aid in reintegration and deter recidivism. John Howard researchers undertook 363 interviews with incarcerated individuals in 2009 and 2010. Among this group, 22.9 percent, or roughly one of every five prisoners, was homeless when incarcerated, that is they were staying in a shelter, living on the street (in places considered unfit for human habitation), in a treatment facility, or staying at the home of a friend, paying no rent. Overall, 32.2 percent, or almost one of every three prisoners had plans upon discharge to go to a shelter, live on the street, or couch-surf at the home of a friend. Another 12 percent of these prisoners are at risk of being homeless since they do not know where they will go.

The report will be released as part of Prisoners Justice Day activities at the Holy Trinity Anglican Church (10 Trinity Square – Bay and Queen – Behind the Eaton Centre) at 12:30pm on August 10^th. Prisoner’s Justice Day is an annual memorial day, dedicated to all those who have lost their lives while in custody.

Researchers Amber Kellen and Sylvia Novac will be among the presenters.

CENTERVILLE, MA–(Marketwire – August 5, 2010) – UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) is very pleased to announce that it has received an order from specialized indoor air quality distributor Puravair for a shipment to the prestigious Miami Anatomical Research Center (“M.A.R.C.”) located in Miami, Florida (www.marctraining.com).

M.A.R.C. is one of the finest medical technology training facilities in the country, offering world class surgical training for a variety of specialties. It is one of the few places in the country offering as many as forty, state-of-the art bio skill lab stations in a hospital style setting alongside custom designed conference and lecture facilities delivering full videoconferencing in a dedicated facility. The introduction of new technologies and medical devices requires constantly evolving expertise and the centre offers training to a huge and skilled market of medical specialists encompassing North, Central and South America, as well as the Caribbean. 

“This order is significant when you consider the client’s needs and perspective,” stated Jack Lennon, President of UV Flu Technologies. “They are an internationally-respected medical facility that instructs a diverse client list of doctors, surgeons and other talented practitioners of the medical profession from throughout the western hemisphere.”

“We trust that other teaching facilities, at home and abroad, will take note and quickly identify that our product offers a cost effective and easy to implement method to increase the overall safety level of any facility by immediately lessening the risk of airborne bacteria, and one that also limits the spread of noxious odors and Volatile Organic Compounds (‘VOC’),” said Mr. Lennon, as he further comments, “The ViraTech UV-400 is specifically designed to kill dangerous strains of bacteria which may present themselves from time to time, while also reducing the levels of other contaminants and odors from the air we breathe.”

Mr. Lennon concluded by saying, “Here is a sale which clearly demonstrates product penetration into a massive market encompassing all forms of medical teaching facilities, as well as businesses such as funeral homes and working pathology labs worldwide. The potential list of users in this sector is huge.”

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO

Click here to see all recent news from this company

WESTPORT, CT–(Marketwire – August 3, 2010) –  Save the Children deployed its rapid response team to the worst-affected and hardest to reach communities in Pakistan’s Swat Valley, where record-breaking monsoon rains have triggered deadly floods and mudslides. The team had to navigate the rushing waters using rafts linked to ropes and pulleys in order to distribute temporary shelters and supplies to stranded children and their families.

The Information Minister of the worst affected province of Khyber Pakthunkhwa, Mian Ifthikar Hussain, estimates 1,500 have been killed by the floods nationwide. Now, officials fear an outbreak of disease among the millions left homeless and without clean water supplies. 

“In nearly all the flood-affected areas, water supplies have been contaminated,” said Annie Foster, Save the Children’s associate vice president for humanitarian response. “There are confirmed reports of diarrhea and cholera that may spread rapidly among the hundreds of thousands who have lost their homes. In this type of environment, children — especially those under five years of age — are the most vulnerable to severe illness and even death.”

Save the Children sent mobile health teams to provide emergency medical aid to treat more than 1,400 people in DI Khan, Buner and the Swat Valley area. The teams travelled by boat and often had to hike many kilometers to remote villages, where roads and bridges had been washed away.

The floods are now heading towards Muzaffargarh, Layyah and DG Khan and Rajanpur, in Punjab. Heavy rains predicted for the first two weeks of August are expected to increase the difficulty of delivering humanitarian aid.

“People are stranded and are rapidly using up their supplies of stored food,” said Foster. “There is a critical need to get more clean water, food and medical assistance to thousands of children and their families in the next few days.”

Save the Children has been working with the children of Pakistan and their families for more than 30 years, and provided assistance to those affected by Tropical Storm Phet in June, the conflict in Khyber-Pakhtunkhwa Province in 2009 and the massive earthquake in 2005.

Donate Now to the Pakistan Children in Emergency Fund or call (800) 728-3843.

Save the Children is the leading, independent organization that creates lasting change for children in need in the United States and around the world. 

NEW YORK, NY–(Marketwire – July 30, 2010) –  Increased demand for testing, new technologies and emerging markets have trumped the economic situation in the world in vitro diagnostics (IVD) market, according to the seventh edition of Kalorama Information’s biennial report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition.” The healthcare market research publisher reported a $44.3 billion market in 2009, and expects growth to be at a rate of six percent for the next five years. 

According to Kalorama the market has already weathered price declines and as a result developed innovative technologies and approaches. This has dulled the impact of a recession which has hurt other industries. Digital pathology, multiplex assays, automation and test service commercialization represent areas where the industry has developed new approaches. The market changes described in the report were on display at the American Association for Clinical Chemistry (AACC) convention in Anaheim, CA this week.

“The convention reflected what we’ve said in the report; that despite economic hard times, the IVD industry is on an upswing,” said Shara Rosen, senior diagnostic analyst for Kalorama Information and author of the study. “A number of world events bode well for the future of testing.”

Trends such as the use of biomarkers and molecular approaches to testing have only increased since the last edition of the report. Consolidation has been a factor in an industry that is dominated by Roche, Siemens, and Abbott. The report notes that 72 percent of the revenue in 2009 was earned by just 18 companies. This hasn’t stopped scores of new companies with unique approaches from competing in diagnostics, according to Kalorama.

The report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition,” has more information on segment market sizes, forecasts, company analyses, and test product development. The report can be found at Kalorama Information at: http://www.kaloramainformation.com/redirect.asp?progid=79398&productid=2613362.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

WINNIPEG, MANITOBA–(Marketwire – July 28, 2010) – DiaMedica Inc., (TSX VENTURE:DMA) today announces the initiation of the Company’s autoimmune program with the success of DM-99 for the treatment of rheumatoid arthritis and other autoimmune diseases.

DM-99 was found to reduce joint swelling by up to 90% (p<0.001) in a collagen induced animal model of rheumatoid arthritis (RA) during the peak of the disease. A single dose of the protein DM-99 administered at the first signs of RA symptoms delayed the onset and severity of the disease. Furthermore, treatment given every forth day appears to have halted the autoimmune attack altogether. 

“We believe that DM-99 is able to activate or increase the number of regulatory T cells (Tregs), which plays a vital role in suppressing the autoimmune attack in a wide range of autoimmune diseases,” commented Dr. Mark Williams, DiaMedica’s Vice President Research.

In a delayed hypersensitivity model, skin inflammation was reduced by 67% (p<0.05) and could be prevented for up to 14 days following a single administration of DM-99. DM-99 also delayed skin graft rejection by several days (p<0.05).

“Based on the ability of DM-99 to modulate the autoimmune attack in several autoimmune diseases, we will be starting a study shortly to determine if our more active form of DM-99, DM-199, can halt or slow the autoimmune attack in type I diabetes. DM-199, may be the only compound that both proliferates beta cells and protects them against the autoimmune attack in type I diabetes,” stated Rick Pauls, President and CEO of DiaMedica.

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments for diabetes and neurological disorders. The Company’s type 2 diabetes program is based on a critical liver nerve signaling mechanism involved in enhancing insulin sensitivity after meal consumption. Two of DiaMedica’s products, DM-71 and DM-99, have previously demonstrated human efficacy in lowering blood sugar levels in people diagnosed with type 2 diabetes based on this novel nerve signaling mechanism.

DiaMedica has expanded its DM-199 recombinant protein program into neurological and autoimmune disorders. The Company has demonstrated that DM-99, the naturally occurring form of DM-199, confers neural protection (protects brain cells) and triggers neural stem cell proliferation (creates brain cells) for the treatment of numerous neurological disorders including Alzheimer’s disease. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions, which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our acquisition of Sanomune may be found in our press releases dated February 18, 2010 and April 20, 2010.